Literature DB >> 23475599

Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?

Andrew J Gawron1, John E Pandolfino.   

Abstract

Diagnosing gastroesophageal reflux disease (GERD) often entails using a combination of patient symptoms, response to proton pump inhibitors (PPI), upper endoscopy, and ambulatory reflux testing. Each of these has limitations of which the clinician must be aware when managing patients with reflux symptoms. Ambulatory reflux monitoring, in particular, can potentially document the true presence of pathologic GERD. Consequently, reflux testing is often necessary in our evaluation of patients with reflux symptoms, and can be useful in distinguishing etiologies driving a lack of response to PPI therapy. Reflux testing results can be also used to guide appropriate PPI prescribing and clinical decision making for appropriate or unnecessary therapy. This review focuses on the limitations of our current diagnostic paradigm and highlights how reflux testing can be helpful in the diagnosis and management of patients with poor response to PPI therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475599      PMCID: PMC3626104          DOI: 10.1007/s11894-013-0316-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  45 in total

1.  Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.

Authors:  N T Gunaratnam; T P Jessup; J Inadomi; D P Lascewski
Journal:  Aliment Pharmacol Ther       Date:  2006-05-15       Impact factor: 8.171

2.  Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

Authors:  J P Galmiche; P Barthelemy; B Hamelin
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

3.  Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database.

Authors:  Ram Dickman; Nora Mattek; Jennifer Holub; Dawn Peters; Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2007-03-22       Impact factor: 10.864

4.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

5.  Heartburn treatment in primary care: randomised, double blind study for 8 weeks.

Authors:  J G Hatlebakk; A Hyggen; P H Madsen; P O Walle; T Schulz; P Mowinckel; T Bernklev; A Berstad
Journal:  BMJ       Date:  1999-08-28

Review 6.  Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group.

Authors:  J E Richter; J E Pandolfino; M F Vela; P J Kahrilas; B E Lacy; R Ganz; W Dengler; B K Oelschlager; J Peters; K R DeVault; R Fass; C P Gyawali; J Conklin; T DeMeester
Journal:  Dis Esophagus       Date:  2012-08-07       Impact factor: 3.429

7.  Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database.

Authors:  Amnon Sonnenberg; Stacey L Amorosi; Michael J Lacey; David A Lieberman
Journal:  Gastrointest Endosc       Date:  2008-01-07       Impact factor: 9.427

8.  New algorithm for the treatment of gastro-oesophageal reflux disease.

Authors:  G N Tytgat; K McColl; J Tack; G Holtmann; R H Hunt; P Malfertheiner; A P S Hungin; H K Batchelor
Journal:  Aliment Pharmacol Ther       Date:  2007-10-31       Impact factor: 8.171

9.  Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.

Authors:  I Mainie; R Tutuian; S Shay; M Vela; X Zhang; D Sifrim; D O Castell
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

10.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.

Authors:  A F Ciccaglione; L Marzio
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

View more
  6 in total

1.  Discontinuation of proton pump inhibitor therapy and the role of esophageal testing.

Authors:  John Pandolfino
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

2.  Is the Routine Use of Impedance Analysis for the Diagnosis of Gastro-Esophageal Reflux Disease More Expensive than Conventional pH Monitoring? Cost Analysis of Two Procedures.

Authors:  Nurkan Törer; Özgür Aytaç
Journal:  Indian J Surg       Date:  2016-01-25       Impact factor: 0.656

Review 3.  The Quality of Care for Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Lara Dakhoul; John E Pandolfino; Rajesh N Keswani
Journal:  Dig Dis Sci       Date:  2016-12-27       Impact factor: 3.199

Review 4.  Chronic cough: a gastroenterology perspective.

Authors:  Andrew J Gawron; Peter J Kahrilas; John E Pandolfino
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2013-12       Impact factor: 2.064

5.  The high frequency of esophageal disorders in Iranian patients with non-cardiac chest pain.

Authors:  Saeed Abdi; Roghayeh Sahraie; Habib Malekpour; Sara Ashatri; Somayeh Jahani-Sherafat; Majid Iranshahi; Mojgan Frootan
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

6.  pH Scores in Hiatal Repair with Transoral Incisionless Fundoplication.

Authors:  Glenn Michael Ihde; Catalina Pena; Christy Scitern; Steve Brewer
Journal:  JSLS       Date:  2019 Jan-Mar       Impact factor: 2.172

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.